more_reports
MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt

MindBio Therapeutics Corp.

LinkedIn We are an innovation company that explores and creates. Through rigorous research and clinical trials, we're building prediction technologies to optimize human health and wellness. We are developing Edge AI hardware-software solutions for the scalable testing of drug and alcohol intoxication.
MBIO:CSE MBQIF:OTCQB WF6:Frankfurt

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page. Please refer to the important disclosures below for additional details.

Recent Articles:

MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets

  ()
MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets.

MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets

  ()
MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential.

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors

  ()
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.

Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) delivers first Edge AI intoxication detection kiosk prototypes for mining, aviation, and construction safety screening.

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.

Biotech Co. Unveils Scalable AI Voice Biomarker Platform

  ()
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) CEO says proprietary AI voice analytics could transform impairment screening across zero-tolerance industries.

More Articles


Experts Following This Company

Stewart Thomson – Galactic Updates

Company News 

6/9/2026 – TechMediaBreaks - MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

6/9/2026 – MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks

6/4/2026 – MindBio Launches Intox AI(TM) in Major Advancement for Drug Use Detection

5/21/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Expands AI Voice Platform with Fatigue Detection Module

5/14/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

5/12/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

5/11/2026 – MindBio Develops Fatigue Prediction Model using Speech Analytics and AI

5/7/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Files Patent Applications for Voice-Based Intoxication Detection

5/5/2026 – MindBio Develops Cross-Language AI Speech Analytics Capability for Intoxication Detection Patent applications filed in 15 world firsts using Voice and AI

4/29/2026 – MindBio Files Patent Applications in 15 World Firsts

4/28/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Deploying AI for Non-Invasive Intoxication Detection

4/20/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Broadens AI Intoxication Detection Platform with Launch of Intox Collect(TM)

4/13/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World's First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening

4/13/2026 – MindBio Deploys New Technology Intox Collect(TM); Expands CNS Drug Detection Capabilities with Voice & Facial Recognition

4/6/2026 – MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets South American Mining Sector as Voice-Based Drug and Alcohol Impairment Screening Platform Moves Toward Commercial Deployment

4/1/2026 – MindBio Announces Closing of Private Placement

3/19/2026 – MindBio Announces Upsize to Private Placement up to $1.5 Million

Important Disclosures
MindBio Therapeutics Corp. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases. The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content. Billboard advertising monthly fees range from $3,000 to $5,000. This landing page contains a summary of the company that was prepared by that company. Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company. The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports. There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page. Readers should conduct their own research for all information publicly available concerning the company. This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.

streetwise book logo Streetwise Company Fact Sheet

streetwise book logoStreetwise - MindBio Therapeutics Corp. Ownership Overview*

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt)

Warrants
Strike PriceNumberExpiry Date
$0.82,506,07111/01/28
Restructures
Date Old Symbol Old Shares New Symbol New Shares
11/06/25 MBIO 400 MBIO 1
*Share Structure & Warrant Information as of 4/29/2026
Investing Highlights
 
MindBio uniquely uses the human voice as a diagnostic tool for screening drug and alcohol intoxication
 
It is at the forefront of AI and speech analytics in this regard being commercially ready with its Booze AI consumer product and the Q2 launch of its Edge AI Enterprise Kiosks for deployment in the mining industry.
 
Expected Q2 2026 testing of Edge AI Kiosks in mining industry, currently in development
 
Tight capital structure, only 4.7mill shares on issue, pre the current raise, post raise under 6 million shares on issue
catalyst Calendar
Q1
2026
Completion of new data collection and analysis technology, now.
Q2
2026
First testing of Edge AI Intox Detection Kiosks in mining industry Q2. 2026
MindBio Therapeutics Corp. Content